Phaseline

Targets › PPARD

PPARD (Peroxisome proliferator-activated receptor delta): drug programs, companies and trials

7 programs from 7 companies in 15 trials: 9 Phase 3, 5 Phase 2, 1 Phase 1; Gastroenterology, Metabolic and endocrine, Oncology; next expected readout Dec 2026.

Ligand-activated transcription factor key mediator of energy metabolism in adipose tissues. Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. (UniProt, Q03181)

Open in Phaseline: the race on PPARD, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
IpsenElafibranor
Peroxisome proliferator-activated receptor alpha agonist; Peroxisome proliferator-activated receptor delta agonist
PPARA, PPARDPhase 3Primary Biliary Cholangitis; Primary Biliary Cirrhosis; Primary Biliary Cholangitis (PBC); Primary Sclerosing CholangitisDec 2026
Inventiva PharmaLanifibranor (IVA337)
Peroxisome proliferator-activated receptor agonist
PPARG, PPARA, PPARDPhase 3NASH - Nonalcoholic SteatohepatitisSep 2027
Assistance Publique - Hôpitaux de ParisBezafibrate
Peroxisome proliferator-activated receptor agonist
PPARG, PPARA, PPARDPhase 3BPCDec 2027
Gilead SciencesSeladelpar
Peroxisome proliferator-activated receptor delta agonist
PPARDPhase 3Primary Biliary Cirrhosis; Primary Biliary CholangitisNov 2028
The First Affiliated Hospital of Xiamen UniversityChiglitazar
Peroxisome proliferator-activated receptor agonist
PPARG, PPARA, PPARDPhase 2Relapsed or Refractory Acute Myeloid Leukemia; Acute Myeloid LeukemiaDec 2026
Shanghai Jiao Tong University School of MedicineChiglitazar
Peroxisome proliferator-activated receptor agonist
PPARG, PPARA, PPARDPhase 2MASH - Metabolic Dysfunction-Associated SteatohepatitisDec 2030
RDC ClinicalLevagen+ (palmitoylethanolamide, PEA)
Lipid signaling molecule; TRPV1 antagonist and PPARδ agonist with anti-inflammatory and ne
TRPV1, PPARDPhase 2Diabetic Peripheral Neuropathy–

Conditions

Primary Biliary Cholangitis (3) Primary Biliary Cirrhosis (2) Primary Sclerosing Cholangitis (2) BPC (2) Primary Biliary Cholangitis (PBC) (1) MASH - Metabolic Dysfunction-Associated Steatohepatitis (1) Relapsed or Refractory Acute Myeloid Leukemia (1) Acute Myeloid Leukemia (1) Diabetic Peripheral Neuropathy (1) NASH - Nonalcoholic Steatohepatitis (1)

Modalities

small molecule (6)

Companies

Ipsen (1) Gilead Sciences (1) Assistance Publique - Hôpitaux de Paris (1) Shanghai Jiao Tong University School of Medicine (1) The First Affiliated Hospital of Xiamen University (1) RDC Clinical (1) Inventiva Pharma (1)

Related targets

PPARA (5) PPARG (4) TRPV1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.